Breaks Categories: News

MondayApr 26, 2021 1:55 pm

PsychedelicNewsBreaks – PsyBio Therapeutics Corp. (TSXV: PSYB) Expands Collaboration with Miami University to Expedite FDA IND Submission

PsyBio (TSXV: PSYB), a biotechnology company pioneering the next generation of targeted psychoactive medications, today announced that it has amended its master sponsored agreement with Miami University based in Oxford, Ohio. The amended agreement extends and expands the research efforts of the laboratory of Dr. J. Andrew Jones in the Department of Chemical, Paper and Biomedical Engineering (the "Jones Lab") to include additional research efforts of the laboratory of Dr. Matthew McMurray in the Department of Psychology (the "McMurray Lab"), and to provide an additional US$1.5 million in funding until May 2023 to Miami University to support all such research.…

Continue Reading

MondayApr 26, 2021 10:50 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces AUD Disorder Indication for Psychedelic Molecule CYB003

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has selected alcohol use disorder (“AUD”) as the initial target indication for its proprietary deuterated psychedelic tryptamine, CYB003. In the announcement, the company noted that its CYB003 new chemical entity (“NCE”) could be an ideal investigational new drug (“IND”) candidate for a future clinical trial focused on AUD after preclinical data has been compiled and evaluated. Cybin is targeting an IND filing for CYB003 by the end of this year. AUD is a relapsing brain disorder often associated with an impaired ability to stop or control alcohol…

Continue Reading

WednesdayApr 21, 2021 10:44 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Data Providing Strong Support to Advance Drug Development Candidates

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that it has successfully demonstrated proof of concept for its deuterated tryptamine programs, CYB003 and CYB004, for the treatment of depression and addiction. According to the update, the U.S. Food and Drug Administration (“FDA”) has granted breakthrough therapy designation to multiple long-acting psychedelic treatments. However, these potential treatments produce extended psychedelic effects that present challenges to patient access and potentially to payer reimbursement. To overcome these issues, Cybin is working to optimize the duration of action of its treatments through the selective deuteration of several…

Continue Reading

TuesdayApr 20, 2021 9:48 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Appointment of New Global Positions

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has appointed two new positions at XP Diagnostics GmbH, its wholly owned German subsidiary. Wolfgang Probst will serve as the company’s new chief operations officer and Manfred Buchberger will be the new head of corporate development. An experienced management and finance consultant with impressive exposure to mergers and acquisitions, corporate re-organizations, and divestitures, Probst has a proven track record of leadership, strategic planning and organizational restructuring. In his new position, he will be responsible for managing the company's…

Continue Reading

WednesdayApr 14, 2021 12:19 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Prepares to Commence Retail Sales of Gummie Products

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, today announced that it has commenced production on approximately 50,000 Pure Chews edible gummie packs. Demand for these types of products is strong in the four provinces (British Columbia, Alberta, Saskatchewan and Ontario) that Pure Extracts is targeting for its retail launch, with approximately $200,000 in revenue estimates associated with this batch. All Pure Chews SKUs, including the 10 mg THC packs of Fire Burst, Strawberry and Mango, utilize a proprietary manufacturing system licensed from…

Continue Reading

TuesdayApr 13, 2021 10:37 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Advancement of IND-Enabling Studies of Psychedelic Molecules for IND Applications

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has plans to advance the preclinical work for two of its deuterated tryptamine development candidates: its orally dissolving tablet (“ODT”) formulation of CYB003 and its inhaled formulation of CYB004. In the announcement, the company noted that the planned studies are part of the required U.S. Food and Drug Administration (“FDA”) enabling trials for investigational new drug applications (“INDs”). The results of the studies will be included in the submissions to the FDA and other regulatory bodies, including Health Canada and European Medical Association (“EMA”). The proprietary Cybin…

Continue Reading

FridayApr 09, 2021 9:23 am

PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Strategic Equity Investment in Psychedelic Journey Center

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology for psychedelic therapy, has announced a follow-up strategic equity investment in ATMC Journey Centers Inc. ("ATMA"), the first government-approved psychedelic journey center in Canada. Earlier this year, MCUR had signed a letter of intent, securing 13% ownership in ATMA; this additional investment retains that ownership. In addition, the company named Mind Cure Health president and CEO Kelsey Ramsden to the ATMA board of directors. MINDCURE’s investment into the pioneering psychedelic journey center is meant to facilitate the use of iSTRYM (“iSTRYM”), which is MCUR’s proprietary…

Continue Reading

ThursdayApr 08, 2021 9:57 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Announces Plans to Launch 1st US Initiative into Dynamic Michigan Market

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, today announced its entry into a letter of intent (“LOI”) with the affiliate of a publicly traded multistate operator (“MSO”) to form a joint venture (the “JV”) to install a cannabis and hemp extraction system in an existing Michigan facility. According to the update, the MSO has a long history of success in Oregon, offering a family of products that include sun-grown and indoor premium flower, along with patented nitro-sealed indoor and sun-grown pre-rolls and…

Continue Reading

WednesdayMar 31, 2021 10:52 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Enters LOI for Psilocybin Extraction, Development of Formulations

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, has inked a letter of intent (“LOI”) to form a joint venture (“JV”) with Psyence Group Inc. (CSE: PSYG). The agreement with Psyence, one of the world’s first psychedelic mushroom companies operating a federally legal commercial cultivation and extraction facility in Southern Africa, calls for the development of high-class techniques for the extraction of psilocybin from psychedelic mushrooms as well as the development of advanced formulations containing psilocybin for the long-term treatment of psychological trauma and…

Continue Reading

TuesdayMar 30, 2021 9:59 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Appoints New Management Positions, Focused on Development and Clinical Operations

Cybin (NEO: CYBN) (OTCQB: CLXPF) announced changes in senior management positions. Cybin US Holdings Inc.’s new chief clinical officer will be Alexander Belser, PhD and its new chief operating officer will be Aaron Bartlone. In addition, co-founder and former COO Paul Glavine has been named chief growth officer and co-founder of Cybin Inc., while former SVP of business development John Kanakis will become chief business officer. The changes are effective immediately. An accomplished biopharmaceutical executive with a proven track record across numerous therapeutic and functional areas, Bartlone has extensive experience with quality assurance, regulatory affairs, product development, compliance and commercial…

Continue Reading